Slide-image and result integrity
Diagnostic decisions ride on whole-slide images and analyzer results - the integrity and source attribution of those artifacts from scanner/analyzer through middleware to LIS must be enumerated and tested.
MedTech segment · Digital Pathology / Lab Automation
Digital Pathology & Lab Automation cybersecurity.
Cybersecurity for whole-slide imaging, AI pathology, and connected lab-automation platforms.
What we mean by digital pathology / lab automation.
Digital pathology and lab automation sit at the intersection of large-image workflows, AI-assisted diagnosis, and deep LIS/LIMS integration. Whole-slide imaging scanners produce multi-gigabyte images that flow into image-management systems and increasingly into FDA-cleared AI modules; lab-automation lines connect pre-analytic, analytic, and post-analytic instruments through middleware that's historically been a recurring CVE source. We build cybersecurity packages tuned to slide-image integrity, AI model governance, and the LIS/LIMS trust boundary.
Threat surface
Cyber risks specific to digital pathology / lab automation.
AI pathology module governance
FDA-cleared AI modules introduce model files, weight delivery, inference servers, and PCCP-governed updates - the SBOM and threat model must treat them as their own subsystem.
Middleware as a recurring CVE source
Vendor middleware between analyzers and LIS/LIMS is a documented recurring source of CVEs and account-credential abuse - continuous monitoring and a postmarket plan that addresses middleware specifically are required.
Cloud review and second-opinion sharing
Pathology cloud platforms that support remote review and second-opinion sharing add multi-tenant authorization and cross-institution data-residency concerns to the threat model.
Attack surface
Attack surface
Digital pathology & lab automation attack surface
Digital pathology and lab automation combine gigabyte-scale slide images, AI-assisted diagnosis, and deep LIS/LIMS integration. Vendor middleware is the recurring CVE source; cloud second-opinion platforms add cross-institution multi-tenancy.
- 01Cloud second-opinion / review
- 02LIS / LIMS
- 03Vendor middleware
- 04AI pathology module (model + weights)
- 05Image-management system
- 06Whole-slide scanner / analyzer
- 07HL7 / ASTM / DICOM-WSI bus
Layers shown outermost (top) to innermost (bottom). Dashed rows are part of the surrounding system but out of scope for this view.
Real-world attacks
Notable real-world attacks & threat scenarios.
Digital pathology and lab-automation incidents combine documented vendor-middleware vulnerabilities (notably BD Synapsys), DICOM and image-management toolkit CVEs, and the broader pattern of HL7/ASTM lab protocols operating without native authentication on hospital networks.
Historical incidents
-
BD Synapsys informatics solution (2022)
CISA advisory ICSMA-22-256-01 disclosed multiple vulnerabilities in BD Synapsys, the laboratory informatics platform, including authentication and authorization weaknesses affecting microbiology lab data and workflow integrity.
CISA ICSMA-22-256-01
-
DICOM and pathology image-management toolkit CVEs
Published CVEs in widely deployed DICOM parsing and image-management libraries (DCMTK, Orthanc, dcm4che, OpenSlide families) repeatedly affect downstream consumers including digital-pathology scanners and image-management systems. Reviewers expect explicit testing of ingest paths and parser robustness, especially as DICOM-WSI deployment broadens.
-
Vendor-middleware credential and remote-service patterns across IVD/lab fleets
Vendor middleware connecting analyzers and pathology scanners to LIS/LIMS has a documented history of credential-custody and service-tunnel incidents across the broader IVD and lab-automation space. The pattern informs how reviewers evaluate digital-pathology postmarket plans.
Active threat scenarios
-
Middleware authentication and authorization abuse
Synapsys-class root cause: lab-informatics middleware with weak auth allows unauthorized reads or modifications to lab data and workflow state - directly affecting result integrity.
-
Slide-image or result substitution end-to-end
Substitution or tampering of slide images or analyzer results anywhere between scanner/instrument and LIS produces a clinical-decision hazard; integrity must be end-to-end, not point-to-point.
-
AI pathology module model or weight tampering
Unsigned or weakly signed model and weight delivery to a cleared AI pathology module allows substitution that changes classification behavior - AAMI CR515:2025 considerations apply.
-
Cloud second-opinion BOLA across institutions
Cross-institution review platforms expose BOLA, tenant-separation, and residency concerns at scale; clinician account takeover compounds the impact.
What FDA reviewers cite
Reviewer talking points from these incidents
- Middleware authentication and authorization explicitly tested and documented (Synapsys reference)
- End-to-end image and result integrity across scanner/instrument, middleware, and LIS
- AI module SBOM, signed weight delivery, and PCCP-governed update path (AAMI CR515:2025)
- Cross-institution cloud sharing tenant separation, BOLA, and residency coverage
Top concerns
Top cybersecurity concerns for digital pathology / lab automation.
Digital pathology and lab automation combine large-image workflows, AI-assisted diagnosis, and deep LIS/LIMS integration with vendor middleware that has historically been a recurring CVE source.
- Slide-image and analyzer-result integrity from scanner/instrument through middleware to LIS
- AI pathology module governance (model files, signed weights, PCCP updates, AAMI CR515:2025)
- Vendor middleware as recurring CVE and credential-abuse source
- HL7/ASTM lab protocols without native authentication
- DICOM-WSI ingest and pathology image-management vulnerabilities
- Cloud second-opinion and remote-review multi-tenancy and cross-institution residency
- Lab-automation track control and robotic-arm safety integration
- EHR result-delivery trust and structured-report write integrity
Operational challenges
Where digital pathology / lab automation teams get stuck.
AI pathology module as its own subsystem
Cleared AI modules carry their own SBOM, model files, inference stack, and PCCP-governed update path; the threat model and submission must treat them distinctly from the host application.
LIS / middleware credential custody
Middleware service accounts and vendor remote-service tooling are the recurring incident pattern in this segment; the postmarket plan must address them as a continuous surface.
Protocol-level compensating controls
HL7/ASTM and many DICOM deployments lack native authentication; the architecture must document and test the compensating network and middleware controls that hold the boundary.
Cloud sharing across institutions
Pathology cloud review platforms cross institutional and jurisdictional boundaries; tenant separation, residency, and BOLA on case data are first-class concerns.
Regulatory pathways and standards
Regulatory pathways
FDA pathways we support
510(k) De Novo
Standards & guidance
Applicable standards
FDA 2026 Premarket Cyber Guidance AAMI SW96 AAMI TIR57 AAMI CR515:2025 (ML-enabled devices) IEC 62304 ISO 14971 DICOM (incl. DICOM-WSI) HL7 / ASTM lab protocols IEC 81001-5-1
Standards & deliverables
What you owe FDA for digital pathology / lab automation - at a glance.
Six deliverables FDA and notified bodies expect across MedTech, with the digital pathology / lab automation-specific wrinkle on each row. Use it as a scoping checklist before you brief vendors or your QA team.
| Deliverable | Status | Cadence | Standard / guidance | Digital Pathology / Lab Automation note |
|---|---|---|---|---|
| SBOM + VEX Machine-readable SBOM (CycloneDX/SPDX) plus VEX feed for every CVE that touches a listed component. |
Required | Premarket + monthly refresh | FDA Cybersecurity Guidance §V · CISA SBOM minimum elements | SBOM must cover scanner/instrument firmware, image-management system, vendor middleware, AI pathology module model and inference stack, and any cloud-review components. |
| Postmarket monitoring Continuous CVE / advisory monitoring against the SBOM, with a documented triage and disclosure path. |
Required | Continuous (≤30-day triage) | FD&C Act §524B · FDA Postmarket Cybersecurity Guidance | Continuous monitoring must include vendor middleware (Synapsys-class) and DICOM/image-management toolkit dependencies as documented CVE sources. |
| Penetration test scope Black/grey-box testing across device, wireless interfaces, mobile apps, cloud APIs, and service tooling. |
Required | Premarket + on material change | AAMI TIR57 · FDA Premarket Cyber Guidance §VI.A.5 | Pen test scope: scanner/analyzer → middleware → LIS chain, AI module model integrity, cross-institution cloud review BOLA, HL7/ASTM bus compensating controls. |
| Threat model STRIDE-per-interface threat model with documented mitigations and residual-risk acceptance. |
Required | Premarket, refreshed each design change | AAMI TIR57 · FDA Premarket Cyber Guidance §V.A | HL7/ASTM/DICOM lack native authentication in many deployments - model network and middleware as compensating controls and test them explicitly. |
| Secure update mechanism Signed firmware/software updates with rollback protection, integrity verification, and staged rollout. |
Required | Designed premarket, exercised lifecycle-long | FDA Cyber Guidance §IV · IEC 81001-5-1 | AI module updates must follow a PCCP with signed weight delivery; AAMI CR515:2025 considerations referenced for ML-enabled modules. |
| Coordinated Vulnerability Disclosure Public CVD policy, intake channel, and SLAs for triage, fix, and customer communication. |
Required | Continuous, lifecycle-long | ISO/IEC 29147 + 30111 · Section 524B(b)(2) | CVD policy must reach lab directors, pathologists, and LIS administrators across multiple institutions in cloud-shared deployments. |
-
SBOM + VEX
RequiredMachine-readable SBOM (CycloneDX/SPDX) plus VEX feed for every CVE that touches a listed component.
- Cadence
- Premarket + monthly refresh
- Standard
- FDA Cybersecurity Guidance §V · CISA SBOM minimum elements
- Digital Pathology / Lab Automation note
- SBOM must cover scanner/instrument firmware, image-management system, vendor middleware, AI pathology module model and inference stack, and any cloud-review components.
-
Postmarket monitoring
RequiredContinuous CVE / advisory monitoring against the SBOM, with a documented triage and disclosure path.
- Cadence
- Continuous (≤30-day triage)
- Standard
- FD&C Act §524B · FDA Postmarket Cybersecurity Guidance
- Digital Pathology / Lab Automation note
- Continuous monitoring must include vendor middleware (Synapsys-class) and DICOM/image-management toolkit dependencies as documented CVE sources.
-
Penetration test scope
RequiredBlack/grey-box testing across device, wireless interfaces, mobile apps, cloud APIs, and service tooling.
- Cadence
- Premarket + on material change
- Standard
- AAMI TIR57 · FDA Premarket Cyber Guidance §VI.A.5
- Digital Pathology / Lab Automation note
- Pen test scope: scanner/analyzer → middleware → LIS chain, AI module model integrity, cross-institution cloud review BOLA, HL7/ASTM bus compensating controls.
-
Threat model
RequiredSTRIDE-per-interface threat model with documented mitigations and residual-risk acceptance.
- Cadence
- Premarket, refreshed each design change
- Standard
- AAMI TIR57 · FDA Premarket Cyber Guidance §V.A
- Digital Pathology / Lab Automation note
- HL7/ASTM/DICOM lack native authentication in many deployments - model network and middleware as compensating controls and test them explicitly.
-
Secure update mechanism
RequiredSigned firmware/software updates with rollback protection, integrity verification, and staged rollout.
- Cadence
- Designed premarket, exercised lifecycle-long
- Standard
- FDA Cyber Guidance §IV · IEC 81001-5-1
- Digital Pathology / Lab Automation note
- AI module updates must follow a PCCP with signed weight delivery; AAMI CR515:2025 considerations referenced for ML-enabled modules.
-
Coordinated Vulnerability Disclosure
RequiredPublic CVD policy, intake channel, and SLAs for triage, fix, and customer communication.
- Cadence
- Continuous, lifecycle-long
- Standard
- ISO/IEC 29147 + 30111 · Section 524B(b)(2)
- Digital Pathology / Lab Automation note
- CVD policy must reach lab directors, pathologists, and LIS administrators across multiple institutions in cloud-shared deployments.
Services
How we help digital pathology / lab automation teams.
FAQs
Digital Pathology / Lab Automation cybersecurity FAQs.
How is digital pathology different from IVD diagnostics for cyber purposes?
IVD diagnostics covers analyzer-led workflows where the analyzer produces a structured result. Digital pathology adds gigabyte-scale image data, AI-assisted diagnosis on top of those images, and a pathologist-in-the-loop review workflow that often spans multiple institutions via cloud second-opinion platforms. The threat model has to address image integrity and AI module governance on top of the LIS integration concerns shared with IVD.
How do you handle FDA-cleared AI pathology modules?
AI modules are scoped as their own subsystem: model file integrity, signed weight delivery, inference-server hardening, update path under a PCCP, adversarial-input resistance, and drift/performance monitoring. The SBOM includes the model and the inference stack, and AAMI CR515:2025 is referenced for ML-enabled device considerations where applicable. Findings tie back to the device-level threat model so the integrated system view stays coherent.
Do you test the analyzer/scanner-to-LIS chain end to end?
Yes. The chain - analyzer or scanner, middleware, LIS/LIMS, EHR result-delivery - is exercised as a single trust boundary. HL7/ASTM and DICOM-WSI traffic are tested for authentication and integrity where the protocol supports it and for compensating controls where it doesn't. Middleware service accounts, vendor remote-service tooling, and the credential-custody story are first-class scope items because they're the recurring source of incidents in this segment.
What about cloud second-opinion and remote-review platforms?
Cloud review platforms are scoped as their own system: multi-tenant authorization, BOLA on case data, clinician account takeover, cross-institution data-residency, and the export/sharing surface. Findings on the cloud are tied back to the scanner threat model so the system view stays coherent for the FDA reviewer and for hospital procurement.
Where does lab automation fit alongside digital pathology?
Lab automation tracks and pre-/post-analytic instruments share the LIS/middleware concerns and the long-deployed-fleet concerns of digital pathology. We scope them together when manufacturers ship both, with automation-specific concerns (track control, robotic-arm safety, sample-handling integrity) called out separately.
How long does a digital-pathology premarket cyber engagement typically take?
For a whole-slide imaging scanner with image-management system and AI module, end-to-end premarket cyber work runs 10-14 weeks. Threat modeling and SBOM front-load in weeks 1-4, pen testing across scanner, image-management, AI module, and LIS integration runs in weeks 4-11, and the consolidated submission package closes in the final weeks - all under a written clearance guarantee.
Digital pathology & lab automation cybersecurity
Ship your scanner, AI pathology module, or automation platform with a defensible cyber package.
Slide-image integrity, AI model governance (AAMI CR515:2025), LIS/middleware testing, and cloud second-opinion assessment.
- 30-min discovery call
- Fixed-fee proposal in 48 hrs
- No sales pressure
Other segments
Explore more MedTech segments
In their words
Backed by MedTech leaders.
HT
"Blue Goat Cyber's depth of expertise was impressive. We had no in-house cybersecurity experience, and their team guided us through every step of the FDA process. The penetration testing and SBOM testing were thorough and gave us complete confidence."
Hank Tucker
CEO · MedTech Manufacturer
For Digital Pathology / Lab Automation
Get Digital Pathology / Lab Automation cybersecurity that lands.
Cybersecurity for whole-slide imaging, AI pathology, and connected lab-automation platforms.